Building better chimeric antigen receptors for adoptive T cell therapy.
Affiliation
Cellular Therapy Group, Cancer Research UK Department of Medical Oncology, Paterson Institute for Cancer Research, Manchester, UK.Issue Date
2010-04
Metadata
Show full item recordAbstract
The last few years have seen the transfer of two decades of research into Chimeric Antigen Receptors (CARs) into clinical trials. Despite this extensive research, there is still a great deal of debate into the optimal design strategy for these, primarily, anti-cancer entities. The archetypal CAR consists of a single-chain antibody fragment, specific to a tumour-associated antigen, fused to a component of the T-cell receptor complex (typically CD3zeta) which on antigen binding primes the engrafted T-cell for anti-tumour activity. The modular nature of these artificial receptors has enabled researchers to modify aspects of their structure, including the extracellular spacer, transmembrane and cytoplasmic domain, to achieve laboratory defined optimal activity. Despite this there is no consensus on the optimal structure, a problem exacerbated by conflicting results using identical receptors. In this review, we provide a structural overview of CAR development and highlight areas that require further refinement. We also attempt to identify possible reasons for conflicting results in the hope that this information will inspire future rational design strategies for optimal tumour targeting using CARs.Citation
Building better chimeric antigen receptors for adoptive T cell therapy. 2010, 10 (2):77-90 Curr Gene TherJournal
Current Gene TherapyPubMed ID
20222863Type
ArticleLanguage
enISSN
1875-5631Collections
Related articles
- T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
- Authors: Jamnani FR, Rahbarizadeh F, Shokrgozar MA, Mahboudi F, Ahmadvand D, Sharifzadeh Z, Parhamifar L, Moghimi SM
- Issue date: 2014 Jan
- Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
- Authors: Han X, Cinay GE, Zhao Y, Guo Y, Zhang X, Wang P
- Issue date: 2017 Nov 1
- Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response.
- Authors: Hombach A, Hombach AA, Abken H
- Issue date: 2010 Oct
- Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects.
- Authors: Shi H, Sun M, Liu L, Wang Z
- Issue date: 2014 Sep 21
- Grafting T cells with tumor specificity: the chimeric receptor strategy for use in immunotherapy of malignant diseases.
- Authors: Hombach A, Pohl C, Reinhold U, Abken H
- Issue date: 1999 Feb